Adlai Nortye Biopharma Co., Ltd.
Adlai Nortye Biopharma Co., Ltd.
Explore linked clinical trials.4 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression | CEACAM5; RAS Mutation; Solid Tumor (Phase I) | Not yet recruiting | Phase 1 | 2026-07-14 | NCT07686445 | |
| An Initial Evaluation of AN8025 in Solid Tumors | Advanced Solid Tumor (Phase 1) | Recruiting | Phase 1 | 2026-06-10 | NCT07639047 | |
| Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations | RAS Mutation; Solid Tumors (Phase 1) | Recruiting | Phase 1 | 2026-06-08 | NCT07252479 | |
| First in Human, Dose Escalation Study of AN4005 | Advanced Lymphoma; Advanced Solid Tumor | Recruiting | Phase 1 | 2025-11-18 | NCT04999384 |